[1] |
FENG Zheng, GUO Qinhao, ZHU Jun, WU Xiaohua, WEN Hao.
Progress in treatment of gynecological cancer in 2023
[J]. China Oncology, 2024, 34(4): 340-360.
|
[2] |
LI Tong, YANG Huijuan.
Progress in diagnosis and treatment of mucinous ovarian cancer
[J]. China Oncology, 2024, 34(1): 90-96.
|
[3] |
WANG Hui, WANG Xia, GAO Yi, XU Jing, YU Xiaojuan, FAN Fangqin, DING Yan, KANG Yu.
Current status and influencing factors of gene screening in first-degree relatives of patients with hereditary breast-ovarian cancer syndrome
[J]. China Oncology, 2023, 33(5): 499-505.
|
[4] |
XIA Lingfang, ZHU Jun, WU Xiaohua.
The latest progress and prospect of gynecological tumor treatment at 2023 ESMO
[J]. China Oncology, 2023, 33(11): 969-980.
|
[5] |
GUO Qinhao, YU Min, WU Xiaohua.
Progress in diagnosis and treatment of gynecological tumors in 2022
[J]. China Oncology, 2023, 33(1): 14-24.
|
[6] |
FENG Zheng, WEN Hao.
Risk-reducing salpingo-oophorectomy for hereditary ovarian cancer
[J]. China Oncology, 2022, 32(11): 1044-1048.
|
[7] |
ZHAO Mingming, WANG Tianyou, WANG Chao.
Progress in menopausal hormone therapy for postoperative patients with gynecological malignant cancer
[J]. China Oncology, 2022, 32(11): 1098-1104.
|
[8] |
LEI Yajie , GAO Yi , WANG Zhijie , CHENG Xi , YANG Yufei , ZHOU Hongyu , CHEN Lihua , CHEN Yixin , LI Haoran , LI Ziting , WU Xiaohua .
Potential role of lymphadenectomy in patients with ovarian cancer (ⅠC-ⅡA): a retrospective trial
[J]. China Oncology, 2021, 31(8): 740-745.
|
[9] |
ZHU Jun, WU Xiaohua.
Leading research progress and prospect of gynecological oncology in 2020
[J]. China Oncology, 2021, 31(4): 250-256.
|
[10] |
CAI Shumo, TANG Jie, HUANG Xiao, HUANG Xiaowei, LIU Suping, KE Guihao, ZHENG Zhong, CHENG Xi, TANG Meiqin.
Three-step chemotherapy treatment for platinum-sensitive recurrent ovarian cancer: a review of 20 cases
[J]. China Oncology, 2021, 31(4): 330-334.
|
[11] |
LIU Yixuan , WEN Zexuan , GUO Lin , LU Renquan .
The function of TTK1 in platinum-resistant ovarian cancer
[J]. China Oncology, 2021, 31(3): 182-191.
|
[12] |
YU Yi, CONG Qing, XU Congjian, JIANG Wei.
The effect of PAFR on cisplatin sensitivity in ovarian cancer cells and its mechanism
[J]. China Oncology, 2021, 31(11): 1063-1071.
|
[13] |
WANG Zhihen , MAO Peimin , JIANG Hongyuan , FAN Lingling .
Assessment of the diagnostic value of CPH-I, CA12-5 and HE4 for cancer prediction in women with ovarian masses with papillary projections diagnosed by ultrasound
[J]. China Oncology, 2020, 30(8): 599-604.
|
[14] |
ZHAO Haiyun, WU Xiaohua.
Research progress of immunotherapy in ovarian cancer
[J]. China Oncology, 2020, 30(7): 538-545.
|
[15] |
WANG Xiaoqin, FU Xinlei, MA Ruyue, YANG Lina, CHEN Yaping, ZHANG Liwen.
Sema3A regulates metastasis through epithelial-mesenchymal transition/matrix metalloproteinase-2 in epithelial ovarian cancer
[J]. China Oncology, 2020, 30(6): 428-434.
|